Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo
Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about half a year after its $150 million Series C. The deal is worth a total ...
View ArticleAragen gets $100M to expand manufacturing footprint
Indian CDMO Aragen Life Sciences has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital. Aragen will use the investment to expand its facilities to meet...
View ArticleNormunity nabs $75M Series B to advance T cell engager and launch first trial
A startup from PD-L1 pioneer Lieping Chen has closed a new financing round. Normunity raised $75 million in a Series B, the company announced Monday, which it hopes to use to ...
View ArticleHengrui and Kailera’s injected incretin posts best-in-class obesity data in...
At 22.8% at 36 weeks, the weight loss seen with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals’ injected GLP-1/GIP dual agonist in its Phase 2 trial looks potentially best-in-class. The candidate...
View ArticleImmunovant’s $450M private placement; Biomea becomes an obesity biotech
Plus, news about Ashvattha, Bausch + Lomb, Whitecap Biosciences, Labviva, Scribe, Sanofi, X4, Apellis and Aileron Therapeutics: Immunovant nets $450M private placement: The proceeds will help afford a...
View ArticleAbbVie partners with Simcere Pharma unit to develop myeloma drug
AbbVie is teaming up with Simcere Zaiming to develop an investigational new drug candidate for multiple myeloma. The agreement, announced Monday, reflects a trend of licensing
View ArticleFederal Circuit upholds Novartis patent for heart drug Entresto
The US Court of Appeals for the Federal Circuit on Friday found a key patent of Novartis' Entresto valid, reversing a lower court ruling and potentially putting up a short-lived roadblock to generic...
View ArticleModerna lowers 2025 revenue estimate, announces more cost cuts
Moderna is slashing its 2025 revenue estimate by $1 billion and expanding cost-cutting measures as it continues to struggle with a slow RSV launch and a shaky Covid-19 vaccine market. Executives are
View ArticleBIO CEO plans to join FDA modernization advisory board under Trump...
John Crowley, CEO of the biotech advocacy group BIO, is slated to join a Trump administration advisory board focused on modernizing the FDA, according to a source familiar with the planning. A...
View ArticleXO Health launches as alternative health plans catch on
Swati Mathai knows it’s a weird time to be launching a health plan startup. The December killing of UnitedHealthcare CEO Brian Thompson laid bare the American public’s fury with ...
View ArticleHealth tech funding in 2025 kicks off with megarounds
Health tech fundraising is making a comeback in the new year after clocking five rounds of over $100 million each. Since the year began, kidney care-focused Evergreen Nephrology has raised ...
View ArticleBiohaven’s protein degrader is promising in early IgAN trial, heads straight...
Interim Phase 1 data on Biohaven’s protein degrader are strong enough that the biotech is planning to move the drug straight into pivotal trials in the kidney disease IgA nephropathy (IgAN). BHV-1400...
View Article#JPM25: Day 2 at the JP Morgan Healthcare Conference
We just wrapped day 2 of JPM. We've been paying close attention to news about the industry's biggest drugmakers. Jaimy Lee had a piece about Pfizer CEO Albert Bourla ...
View ArticleDaiichi Sankyo brings Glycotope antibody in-house for $132.5M
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope. The one-off fee “satisfies” all milestone and royalty payments due to Glycotope under...
View ArticleAfter GSK deal, IDRx chair takes investing role at Curie.Bio
SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his "free the founders" startup accelerator Curie.Bio, they...
View ArticleHealth insurers, pharmacy giants sit out JP Morgan Healthcare Conference
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way to start the new year. How the week plays out ...
View ArticleAnavex reports long-term Alzheimer's data for drug with history of scrutiny
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative and CNS disorders, reporting long-term Phase 2/3 Alzheimer’s data Monday. The...
View ArticleCan the Pfizer machine fight back against an activist investor?
Pfizer says it’s back on track. After a tumultuous 2024 filled with more cost cuts, an activist investor, a pulled drug and executive changes, CEO Albert ...
View Article